Related Experiment Video
Updated: Aug 15, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Cell-specific inhibition of paramyxovirus maturation by proteasome inhibitors
Hitoshi Watanabe1, Yoshikazu Tanaka, Yukie Shimazu
1Department of Virology, Graduate School of Biomedical Sciences, Hiroshima University 1-2-3 Kasumi, Minami-ku, Hiroshima, Japan.
Abstract:
Effects of proteasome inhibitors on the replication of a paramyxovirus in comparison with the effects on replication of an orthomyxovirus and rhabdovirus were investigated. Treatment of Sendai virus (SeV)-infected LLC-MK2 cells with 50 microM MG132 reduced virus growth to ca. 1/10,000, and treatment with different concentrations of MG132 reduced virus growth in a dose-dependent manner. Released amounts of viral proteins were reduced in correspondence with decrease in infectivity. The inhibition of virus maturation was confirmed by an SeV-like particle formation system. Lactacystin also impaired SeV growth and zLL impaired the growth to a lesser extent, suggesting involvement of proteasomes in the restriction of virus growth. In the presence of MG132, localizations of the M protein and viral F and HN glycoproteins on the cell membrane appeared to be partly dissociated, although the viral glycoproteins were normally transported to the cell surface. These results suggest that an early step of SeV assembly was disturbed by proteasome inhibitors. The relationship of the results with ubiquitin is also discussed. SeV maturation was less susceptible and resistant to MG132 in CV1 cells and A549 cells, respectively, indicating cell specificity of the drug effect. Release of vesicular stomatitis virus also showed high susceptibility to MG132 and release of influenza virus A/WSN/33 was only mildly susceptible to the drug in LLC-MK2 cells. Effects of proteasome inhibitors on virus maturation are thus highly cell-specific and partly virus-specific.
Insights
Proteasome inhibitors significantly impede Sendai virus (SeV) replication and maturation by disrupting early assembly steps. This antiviral effect is highly cell-specific and virus-specific, impacting paramyxoviruses more than orthomyxoviruses or rhabdoviruses.
Area of Science:
- Virology
- Cell Biology
- Biochemistry
Background:
- Proteasomes play crucial roles in cellular protein degradation.
- The impact of proteasome inhibitors on paramyxovirus replication is not fully understood.
- Investigating drug effects on viral replication aids in developing antiviral strategies.
Purpose of the Study:
- To investigate the effects of proteasome inhibitors on Sendai virus (SeV) replication.
- To compare these effects with those on orthomyxovirus and rhabdovirus replication.
- To elucidate the specific stages of viral replication affected by proteasome inhibition.
Main Methods:
- LLC-MK2 cells infected with Sendai virus (SeV) were treated with MG132, Lactacystin, and zLL.
- Viral protein levels and infectivity were measured.
- An SeV-like particle formation system was used to assess virus maturation.
- Cell-specific effects were evaluated using CV1 and A549 cells.
- Comparative studies included vesicular stomatitis virus and influenza virus A/WSN/33.
Main Results:
- MG132 significantly reduced SeV growth in a dose-dependent manner, decreasing viral protein release and infectivity.
- Proteasome inhibition disturbed early SeV assembly, affecting M protein and glycoprotein localization.
- Virus maturation was impaired, as confirmed by the SeV-like particle system.
- The susceptibility to MG132 varied significantly across different cell types (LLC-MK2, CV1, A549) and viruses (SeV, vesicular stomatitis virus, influenza virus).
Conclusions:
- Proteasome inhibitors disrupt early Sendai virus assembly and maturation.
- The antiviral efficacy of proteasome inhibitors is both cell-specific and virus-specific.
- These findings highlight the potential of targeting proteasomes for antiviral therapy, with careful consideration of host cell and viral factors.
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Leaky Scanning

